Elasmogen
Elasmogen is a biopharmaceutical company developing soloMER conjugates for the treatment of immune-mediated inflammatory diseases. The company's lead candidate, ELN28, is a dual-acting biologic that combines TNFα blockade with localized JAK inhibition. Its primary target market is patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition with significant unmet medical needs.
Biotechnology
Pharmaceuticals
Healthcare
Drug Discovery
Funding summary
- Total raised
- €2.3M
- Funding rounds
- 1
Investors in Elasmogen
Investors on record for Elasmogen. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Elasmogen?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors